This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

38/100

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Compared to CN, we identified 32 differential metabolites in AD and 49 in MCI serum. Notably, differential metabolites related to AA, organic acid, FA, phosphatidylcholine (PC), sphingomyelin (SM) metabolism in AD and free fatty acid (FFA), acylcarnitine, PC, SM in MCI were strongly associated with cognitive level, memory, attention and execution function as evaluated by scales including Mini-Mental State Examination (MMSE), the Alzheimer's Disease Assessment Scale-cognitive Section (ADAS), the Montreal Cognitive Assessment (MoCA), the Clinical Dementia Rating (CDR), the Auditory Verbal Learning Test (AVLT) and the Trail Making Test (TMT). Pathway analysis based on the differential metabolites revealed perturbation in pathways related to phospholipid metabolism, sphingolipid metabolism, amino acids (AAs) metabolism, beta oxidation of FAs, and carnitine metabolism. Using random forest (RF), support vector machine (SVM) and Boruta analysis for classification and validated by gradient boosting (GB), logistic regression (LR) and random forest diagnostic model, we identified panels of 10 metabolites in AD and 13 metabolites in MCI that effectively discriminate AD and MCI individuals from CN with high accuracy, sensitivity and specificity. In summary, this novel study combing metabolomics and lipidomics approaches and found that perturbations in serum sphignolipids, glycerophospholipids, AAs, FFA and acylcarnitines are consistently associated with pathology and progression of AD and MCI. These metabolic biomarkers provided promising molecular targets for the early diagnosis and treatment of AD and MCI.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mai, Y., Cao, Z., Yu, Q., & Liu, J. (2025). Metabolomics and lipidomics study on serum metabolite signatures in Alzheimer's disease and mild cognitive impairment. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_104134

Vancouver

Mai Y, Cao Z, Yu Q, Liu J. Metabolomics and lipidomics study on serum metabolite signatures in Alzheimer's disease and mild cognitive impairment. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_104134. PMID: 41453218.

BibTeX

@article{mai2025-41453218,
  author  = {Mai, Yingren and Cao, Zhiyu and Yu, Qun and Liu, Jun},
  title   = {{Metabolomics and lipidomics study on serum metabolite signatures in Alzheimer's disease and mild cognitive impairment}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_104134},
  pmid    = {41453218},
  url     = {https://doi.org/10.1002/alz70856_104134}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Compared to CN, we identified 32 differential metabolites in AD and 49 in MCI serum.
Notably, differential metabolites related to AA, organic acid, FA, phosphatidylcholine (PC), sphingomyelin (SM) metabolism in AD and free fatty acid (FFA), acylcarnitine, PC, SM in MCI were strongly associated with cognitive level, memory, attention and execution function as evaluated by scales including Mini-Mental State Examination (MMSE), the Alzheimer's Disease Assessment Scale-cognitive Section (ADAS), the Montreal Cognitive Assessment (MoCA), the Clinical Dementia Rating (CDR), the Auditory Verbal Learning Test (AVLT) and the Trail Making Test (TMT).
Pathway analysis based on the differential metabolites revealed perturbation in pathways related to phospholipid metabolism, sphingolipid metabolism, amino acids (AAs) metabolism, beta oxidation of FAs, and carnitine metabolism.
Using random forest (RF), support vector machine (SVM) and Boruta analysis for classification and validated by gradient boosting (GB), logistic regression (LR) and random forest diagnostic model, we identified panels of 10 metabolites in AD and 13 metabolites in MCI that effectively discriminate AD and MCI individuals from CN with high accuracy, sensitivity and specificity.
In summary, this novel study combing metabolomics and lipidomics approaches and found that perturbations in serum sphignolipids, glycerophospholipids, AAs, FFA and acylcarnitines are consistently associated with pathology and progression of AD and MCI.

Why it matters

This study identified panels of 10 metabolites in Alzheimer's disease and 13 in mild cognitive impairment that distinguished these groups from cognitively normal controls with high accuracy. These are blood-based metabolite signatures for classification, not a treatment or cure.

Study details

Participants22
Evidence strengthModerate

How this study scored 38/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 36 of the 96 points we could judge it on, which is 38 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	1 / 4	22 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 1 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.3 citations a year over 3 year(s) since 2025
Impact for its field and year	1 / 6	Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Jun Liu holds only 2 work(s), too few to judge a track record — left out of this score
Institution's track record	0 / 3	Second Affiliated Hospital of Guangzhou Medical University: institution h-index 186 (OpenAlex)
Multicenter collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41453218)
Free to read	2 / 2	Free to read
Points	36 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 36 of the 96 points we could judge it on is 38 out of 100.
Total	38 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Mild cognitive impairment

Also tagged “cerebrospinal”

821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →